Polish healthtech startup Holi has secured €3 million in seed funding led by 4growth VC to expand its data-driven digital obesity treatment platform into new European markets.
👯 Founders: Paweł Seweryn (Founder & CEO), Jan Kundziołka (Co-Founder, Product & Technology)
📅 Founding year: 2023
🏭 Industry: Healthtech
💥 Problem: Obesity affects more than 800 million people worldwide and is projected to nearly double by 2035. Current treatments often lack coordination, continuity, and personalization, leading to poor long-term outcomes and high costs.
📣 Solution: Holi provides a digital obesity clinic that integrates medical expertise (doctors, psychodietitians, psychologists, physiotherapists) with technology and GLP-1-based pharmacotherapy (e.g., Ozempic, Wegovy). Patients receive personalized treatment plans, behavioral support, and real-time therapy adjustments through a mobile app and online platform.
👥 Customers: Individuals living with obesity or overweight, primarily in European markets seeking accessible and continuous private healthcare.
🌱 Stage: Seed
💰 Investment amount: €3 million
🚀 Funded by: Lead investor 4growth VC (Poland), with participation from YZR Capital (Germany), Heartfelt Capital (Germany), and several business angels.
👁️🗨️ Investor’s perspective: “Obesity remains one of the most underserved health needs globally. Holi has built a truly efficient care model – virtual, scalable and designed with a genuine value-for-money mindset. It delivers clinically proven outcomes at a price point that makes sense for both patients and the business.” — Krzysztof Bachta, Managing Partner, 4growth VC
💡 It will be spent on:
– Expanding into new European markets (Southern and Eastern Europe);
– Scaling medical infrastructure;
– Enhancing technology: diagnostics integration, GLP-1 tracking, automation of care processes, and engagement features to sustain patient motivation;
💬 In their own words:
“Our goal is to deliver a comprehensive solution that leads to real, long-term change in metabolic health. The funding will enable us to scale internationally while further developing our technology stack.” — Paweł Seweryn, Founder & CEO
“The next generation of obesity treatment will be hybrid – data and AI for precision, experts for impact.” — Jan Kundziołka, Co-Founder
💪 Their specialty: Hybrid obesity treatment that combines data-driven care, behavioral coaching, and GLP-1 optimization to achieve stronger outcomes and reduce medication costs.
🔑 Business model: Subscription-based digital clinic model offering multidisciplinary medical care and pharmacotherapy with continuous monitoring and personalized treatment.
👩🏫 Market: European obesity treatment market valued at EUR 40–50 billion, driven by the adoption of GLP-1 drugs and growing private healthcare spending.
📊 Traction:
– Several thousand patients treated;
– Average 17% weight reduction after 12 months — ~1.5× better than GLP-1 treatment alone;
– Patients reduce medication costs by up to 50%;
